Huntington's Disease Market: Steady Growth Ahead as Gene-Silencing and RNA-Targeted Pipeline Advances by 2036

DelveInsight's "Huntington's Disease Market Insights, Epidemiology, and Market Forecast-2036" report offers an in-depth understanding of Huntington's disease, historical and forecasted epidemiology, as well as Huntington's Disease market trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

To know more about the Huntington's Disease market outlook, drug uptake, treatment scenario, and epidemiology trends, visit: https://www.delveinsight.com/sample-request/huntingtons-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Key Highlights from the Huntington's Disease Market Report
• The Huntington's Disease market was valued at approximately USD 320 million in 2025 and is projected to grow at a CAGR of around 14% during 2026-2036.
• AUSTEDO (Teva Pharmaceuticals) generated the highest revenue among approved therapies in 2025, contributing approximately USD 167 million.
• In September 2025, Skyhawk Therapeutics reported positive interim Phase I results for SKY-0515, demonstrating dose-dependent reductions in mutant huntingtin (mHTT) protein.
• In January 2026, Skyhawk Therapeutics expanded the FALCON-HD Phase II/III trial globally after encouraging nine-month interim results, with more than 90 patients treated.
• In March 2025, PTC Therapeutics announced positive Phase II PIVOT-HD results for Votoplam (PTC518), meeting its primary endpoint for reducing Huntingtin (HTT) protein levels.
• In December 2024, Novartis entered a global licensing and collaboration agreement with PTC Therapeutics for PTC518, a potential oral disease-modifying therapy.
• In May 2024, the FDA approved AUSTEDO XR, a once-daily treatment option for Huntington's disease chorea.
• In August 2023, the FDA approved INGREZZA (Neurocrine Biosciences) for chorea in adults with Huntington's disease.
• The United States recorded approximately 44,000 prevalent Huntington's disease cases in 2025, while the EU4 and the UK together reported approximately 37,000 cases.
• Across the 7MM, nearly 50% of Huntington's disease cases occur in individuals aged 60 years and above.
• Key companies include Teva Pharmaceuticals, Neurocrine Biosciences, Novartis Pharmaceuticals, Skyhawk Therapeutics, Alnylam Pharmaceuticals, Roche, and UniQure Biopharma.
• Key therapies include AUSTEDO, INGREZZA, SKY-0515, Votoplam (PTC518), Pridopidine, and ANX005.
• Among anticipated launches, INGREZZA and ANX005 (tanruprubart) are expected to capture significant market share during the forecast period.

Huntington's Disease Overview
Huntington's disease is a rare, inherited, progressive neurodegenerative disorder caused by a mutation in the HTT gene on chromosome 4. The mutation results in the production of abnormal huntingtin protein, leading to gradual nerve cell damage in the brain.
The disease follows an autosomal dominant inheritance pattern, meaning each child of an affected parent has a 50% chance of inheriting the mutation.
Common symptoms include:
• Involuntary movements (chorea)
• Cognitive decline
• Depression and anxiety
• Irritability and behavioral changes
• Progressive loss of motor function

Diagnosis involves:
• Clinical evaluation
• Family history assessment
• Genetic blood testing
• CT or MRI imaging
While no cure currently exists, available treatments focus on symptom management and supportive care throughout disease progression.

Get a free sample of the Huntington's Disease Market Report: https://www.delveinsight.com/sample-request/huntingtons-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Huntington's Disease Epidemiology Insights
The epidemiology section analyzes historical and projected patient populations across the 7MM and identifies trends influencing disease burden through 2036.
According to DelveInsight:
In the United States, prevalent Huntington's disease cases reached 44,000 in 2025 and are expected to increase during the forecast period. EU4 and the UK together reported approximately 37,000 prevalent cases in 2025.
Additional epidemiology insights include:
• Advanced Stage IV and Stage V cases remain comparatively limited, particularly in Japan.
• Approximately 80 Stage IV and 20 Stage V cases were estimated in Japan during 2025.
• Individuals aged 60 years and older account for roughly half of all Huntington's disease cases across the 7MM.

Epidemiology Segmentation
The report evaluates:
• Total Prevalent Cases of Huntington's Disease
• Total Diagnosed Prevalent Cases of Huntington's Disease
• Age-Specific Cases of Huntington's Disease
• Stage-Specific Cases of Huntington's Disease
• Total Treated Cases of Huntington's Disease

Download the report to explore Huntington's Disease epidemiology trends: https://www.delveinsight.com/sample-request/huntingtons-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Huntington's Disease Therapies and Key Companies
• AUSTEDO (deutetrabenazine) - Teva Pharmaceuticals
• INGREZZA (valbenazine / NBI-98854) - Neurocrine Biosciences
• SKY-0515 - Skyhawk Therapeutics
• Votoplam (PTC518) - Novartis Pharmaceuticals
• Pridopidine - Novartis Pharmaceuticals
• ANX005 (tanruprubart) - Alnylam Pharmaceuticals

Emerging Huntington's Disease Drugs Uptake
The report analyzes the expected adoption of emerging therapies between 2026 and 2036, including anticipated patient uptake and commercial performance.
Key pipeline therapies include:
• SKY-0515: An oral RNA modulator developed using Skyhawk's SKYSTAR platform that reduces both HTT protein and PMS1 protein, targeting disease progression.
• Votoplam (PTC518): A small-molecule splicing modifier that promotes Huntingtin mRNA degradation and has demonstrated favorable safety and dose-dependent HTT reduction.
• ANX005 (tanruprubart): An investigational therapy expected to gain meaningful market share following potential approval.
The treatment landscape is steadily shifting from symptomatic management toward gene-silencing and RNA-targeted disease-modifying therapies.

Discover therapies expected to gain significant Huntington's Disease market share: https://www.delveinsight.com/sample-request/huntingtons-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Huntington's Disease Market Forecast
The current Huntington's Disease treatment landscape includes approved therapies for chorea, such as:
• AUSTEDO
• AUSTEDO XR
• INGREZZA
• Generic Tetrabenazine
These therapies primarily address symptoms rather than slowing disease progression.

Key Huntington's Disease Market drivers include:
• Advancements in gene-silencing and RNA-based therapies.
• Improved awareness and genetic testing enabling earlier diagnosis.
• A strong pipeline of disease-modifying therapies, including SKY-0515 and Votoplam.
• Increased investment in rare neurological disorders.
• Favorable regulatory incentives, including orphan drug designations and expedited approval pathways.
These factors are expected to support sustained market growth through 2036.

Scope of the Huntington's Disease Market Report
• Study Period: 2022-2036
• Coverage: 7MM (United States, EU4, United Kingdom, and Japan)
• Key Companies: Teva Pharmaceuticals, Neurocrine Biosciences, Novartis Pharmaceuticals, Skyhawk Therapeutics, Alnylam Pharmaceuticals, Roche, UniQure Biopharma, and others.
• Key Therapies: AUSTEDO, INGREZZA, SKY-0515, Votoplam (PTC518), Pridopidine, ANX005, and others.
• Therapeutic Assessment: Current marketed and emerging therapies.
• Market Dynamics: Drivers and barriers.
• Competitive Intelligence: SWOT Analysis, PESTLE Analysis, Porter's Five Forces, Conjoint Analysis, and Market Entry Strategies.
• Additional Insights: Unmet needs, KOL views, analyst perspectives, market access, and reimbursement analysis.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432, Las Vegas, NV, United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading healthcare business consulting and market research firm focused exclusively on the life sciences sector. The company supports pharmaceutical, biotechnology, and medical device organizations with comprehensive market intelligence, competitive analysis, epidemiology forecasts, pipeline assessments, and strategic consulting services to accelerate business growth and support informed decision-making.

This release was published on openPR.